Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

JPMorgan expects Sartorius Vz. to beat Q3 and sees AI labs as next growth opportunity

JPMorgan reiterates its overweight rating on Sartorius Vz. with a €295 price target and expects a slight beat of market expectations in the third quarter. Sartorius had confirmed currency-adjusted revenue growth of 5–9% for 2026; Bioprocess Solutions is expected to grow 6–10%. Analysts see the opening of AI labs as the next long-term growth opportunity for the company. » More on finanzen.net
Sartorius vz pays 0.74 EUR dividend for 2025

At the annual general meeting, a dividend of 0.74 EUR per ordinary share was approved for the 2025 fiscal year, unchanged from the previous year, totaling 50.70 million EUR. The dividend yield is 0.30 percent (previous year 0.34 percent); the stock is marked down on the ex-dividend day, with payment made shortly afterwards. Over five years the share lost about 49.6 percent, and total return including dividends is -49.26 percent. FactSet expects a dividend of 0.91 EUR for 2026 and a yield of around 0.42 percent. » More on finanzen.net
Sartorius up sharply pre-market after mid-term targets

The new mid-term targets from Sartorius were received positively in pre-market trading; the stock rose on Tradegate by 3.7% to €216.70. JPMorgan analyst Richard Vosser comments that the targets imply a consensus EBITDA figure through 2030 that is 4% lower, while forecasts for subsidiary Sartorius Stedim remained unchanged. RBC analyst Charles Weston highlights the Bioprocess Solutions segment, which is at the center of investor attention and is expected to be above consensus expectations. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sartorius (Vz) has already paid €0.74 in dividends. The last payout was in March.

Financials

In the last quarter, Sartorius (Vz) had revenue of €926.3M and net profit of €66.1M

(EUR)	September 2026	YoY
Revenue	926.3M	9.86%
Gross profit	420.8M	7.02%
Net profit	66.1M	50.91%
EBITDA	274M	15.13%

Fundamentals

Metric	Value
Market capitalization	€17.88B
Number of shares	61.77M
52-week high/low	€289.50 - €198.50
Dividend yield	0.26%
Dividends TTM	€0.74
Beta	1.45
P/E ratio	91.61
PEG ratio	1.44
P/B ratio	6.82
P/S ratio	4.88

Company profile

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Name	Sartorius (Vz)
CEO	Michael Grosse
Headquarters	Göttingen, ni Germany
Website	sartorius.de
Sector	Health Care
Industry	Life Sciences Tools & Services
IPO	04/28/1999
Employees	14,279